Arvinas (ARVN) Q3 2026: Expense Discipline Extends Runway as Pipeline Catalysts Approach

Key Takeaways

• Arvinas reported a third-quarter 2026 GAAP net loss of $53.9 million, or $0.82 per share, compared with a net loss of $35.1 million, or $0.48 per share, a year earlier; the per-share result still beat consensus estimates.
• Quarterly revenue fell to $0.5 million from $41.9 million a year ago, as deferred Pfizer vepdegestrant collaboration revenue and a prior-year Novartis milestone did not recur.
• Operating expenses declined sharply, with total costs at $59.6 million versus $85.7 million a year earlier, reflecting disciplined capital allocation.
• Cash, cash equivalents, restricted cash, and marketable securities totaled $558.9 million as of September 30, 2026, with runway guided into the second half of 2028.
• Management reaffirmed multiple near-term clinical catalysts, including ARV-393 data at the December 2026 ASH conference and further readouts in 2027.

Why This Quarter Matters for ARVN

Arvinas is a clinical-stage biotechnology company pioneering targeted protein degradation through its PROTAC platform, which harnesses the body’s natural protein-disposal system. With no approved products yet, investors focus on expense control, cash runway, and pipeline execution rather than top-line sales. This quarter stood out because revenue reset to royalty-only levels after prior collaboration payments were recognized, making the update a key checkpoint on whether management is preserving resources while advancing programs toward meaningful data readouts.

Breaking Down the Reported Numbers

For the third quarter ended September 30, 2026, ARVN posted revenue of $0.5 million, down from $41.9 million in the prior-year period. The drop stemmed from the absence of roughly $20.6 million in Pfizer vepdegestrant collaboration revenue and a $20.0 million Novartis milestone booked a year earlier. Current revenue came almost entirely from the first sales-based royalty payment under the Rigel Pharmaceuticals license agreement.

The company recorded a GAAP net loss of $53.9 million, or $0.82 per basic and diluted share, versus a net loss of $35.1 million, or $0.48 per share, in the third quarter of 2025. Although the loss widened, the per-share figure exceeded consensus estimates. The increase in net loss largely reflected the missing collaboration and milestone revenue plus lower interest income, even as operating expenses decreased.

Cost management was a positive note. GAAP R&D expense dropped to $46.9 million from $64.7 million, helped by a $14.2 million reduction in vepdegestrant spending. GAAP G&A expense fell to $12.6 million from $21.0 million. Total operating expenses reached $59.6 million compared with $85.7 million a year earlier. The company closed the quarter with $558.9 million in cash and marketable securities and confirmed that its balance sheet should support operations into the second half of 2028.

Market Reaction and Near-Term Focus

Shares of ARVN moved lower after the release as investors balanced the wider net loss and revenue miss against the clear improvement in spending discipline and the extended cash runway. For a clinical-stage biotech, the revenue shortfall was largely expected given the structural shift in its revenue model. Attention quickly turned to the pipeline, where management highlighted upcoming data from the BCL6, polyQ-AR, and HPK1 programs in late 2026 and 2027.

Pipeline Catalysts on the Horizon

The nearest milestone is ARV-393, the oral BCL6 degrader for lymphoma, with initial Phase 1 monotherapy dose-escalation data slated for the American Society of Hematology annual meeting in December 2026. Investors will look for safety, tolerability, target engagement, and early efficacy signals in T-cell lymphoma, followed by a fuller B-cell dataset in mid-2027.

Two other Phase 1 programs are progressing. ARV-027, an oral androgen-receptor degrader for spinal-bulbar muscular atrophy, should deliver initial healthy-volunteer data and begin patient dosing in the first half of 2027. ARV-6723, an oral HPK1 degrader in immuno-oncology, started patient dosing in the third quarter, with first data expected in the second half of 2027.

ARV-102, the LRRK2 degrader for neurodegenerative disease, remains on clinical hold in the United States. The company now plans to prioritize a Phase 1b trial in progressive supranuclear palsy in the European Union and United Kingdom, subject to regulatory approval. Resolution of the U.S. hold and trial start timing will be worth monitoring.

Expense trends and cash burn will also stay in focus. With revenue now mainly royalty-based, ARVN’s valuation will depend increasingly on clinical execution and the ability to maintain runway through disciplined spending ahead of multiple data readouts in 2027.

Using AI Tools in My Research Process

I also checked this using Tickeron’s AI Screener to see how ARVN compares to other biotechnology names on key fundamentals and technical signals. As part of my routine research, I often turn to Tickeron’s AI-powered tools to quickly surface comparable opportunities and confirm broader market context before diving deeper into individual company filings.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume